Oppenheimer restated their buy rating on shares of Baxter International (NYSE:BAX) in a research note released on Thursday morning, AnalystRatings.com reports.
Other equities analysts have also recently issued reports about the company. Barclays restated a hold rating and set a $84.00 target price on shares of Baxter International in a report on Tuesday, April 14th. Piper Sandler raised their price objective on shares of Baxter International from $90.00 to $100.00 and gave the company an overweight rating in a research note on Thursday, April 30th. TheStreet raised shares of Baxter International from a c+ rating to a b+ rating in a research note on Thursday, April 30th. UBS Group raised their price target on shares of Baxter International from $95.00 to $103.00 and gave the company a buy rating in a research report on Friday, May 1st. Finally, SVB Leerink upped their price objective on Baxter International from $96.00 to $105.00 and gave the stock an outperform rating in a research report on Friday, May 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $96.72.
NYSE BAX opened at $86.38 on Thursday. Baxter International has a 12 month low of $69.10 and a 12 month high of $95.19. The stock has a market capitalization of $43.81 billion, a P/E ratio of 26.10, a PEG ratio of 2.76 and a beta of 0.84. The firm’s 50-day moving average is $86.00 and its two-hundred day moving average is $86.95. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.74 and a quick ratio of 2.19.
Baxter International (NYSE:BAX) last announced its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.64 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.07). Baxter International had a net margin of 8.10% and a return on equity of 21.02%. The firm had revenue of $2.72 billion during the quarter, compared to analysts’ expectations of $2.86 billion. During the same period in the previous year, the firm earned $0.89 EPS. The firm’s revenue for the quarter was down 4.3% compared to the same quarter last year. As a group, analysts anticipate that Baxter International will post 3.07 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Monday, August 31st will be paid a dividend of $0.245 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.98 annualized dividend and a yield of 1.13%. Baxter International’s dividend payout ratio is currently 29.61%.
In other news, SVP Andrew Frye sold 3,742 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $91.00, for a total value of $340,522.00. Following the completion of the sale, the senior vice president now directly owns 16,216 shares of the company’s stock, valued at $1,475,656. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John D. Forsyth sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $82.95, for a total transaction of $124,425.00. Following the transaction, the director now owns 35,398 shares in the company, valued at $2,936,264.10. The disclosure for this sale can be found here. Insiders sold 77,583 shares of company stock valued at $6,613,932 in the last 90 days. 0.13% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Jaffetilchin Investment Partners LLC acquired a new stake in shares of Baxter International during the second quarter worth about $44,000. Campbell Wealth Management purchased a new stake in Baxter International during the 2nd quarter valued at approximately $26,000. Allworth Financial LP lifted its position in Baxter International by 118.9% during the 2nd quarter. Allworth Financial LP now owns 313 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 170 shares during the period. Financial Management Professionals Inc. purchased a new position in shares of Baxter International in the 2nd quarter valued at approximately $28,000. Finally, Creative Financial Designs Inc. ADV acquired a new position in shares of Baxter International in the second quarter valued at approximately $30,000. Institutional investors own 83.74% of the company’s stock.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.